The partnership with the Department of Health – Abu Dhabi and M42 will help AbbVie expand its presence in the UAE and advance its personalized medicine and genomics initiatives. This collaboration is likely to have a positive impact on AbbVie's stock price in the short term as it demonstrates the company's commitment to innovation and growth in the healthcare sector.